Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Circulating melanoma cells as a predictive biomarker.

Karakousis G, Yang R, Xu X.

J Invest Dermatol. 2013 Jun;133(6):1460-2. doi: 10.1038/jid.2013.34.

2.

Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.

Khoja L, Lorigan P, Zhou C, Lancashire M, Booth J, Cummings J, Califano R, Clack G, Hughes A, Dive C.

J Invest Dermatol. 2013 Jun;133(6):1582-90. doi: 10.1038/jid.2012.468. Epub 2012 Dec 6.

3.

Circulating tumor cells and melanoma progression.

Xu X, Zhong JF.

J Invest Dermatol. 2010 Oct;130(10):2349-51. doi: 10.1038/jid.2010.215.

4.

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.

Gray ES, Reid AL, Bowyer S, Calapre L, Siew K, Pearce R, Cowell L, Frank MH, Millward M, Ziman M.

J Invest Dermatol. 2015 Aug;135(8):2040-2048. doi: 10.1038/jid.2015.127. Epub 2015 Apr 1.

5.

Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.

Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, Elashoff R, Mozzillo N, Kelley MC, Thompson JF, Lee JE, Hoon DS.

Ann Surg. 2012 Feb;255(2):357-62. doi: 10.1097/SLA.0b013e3182380f56.

6.

Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma.

Klinac D, Gray ES, Freeman JB, Reid A, Bowyer S, Millward M, Ziman M.

BMC Cancer. 2014 Jun 11;14:423. doi: 10.1186/1471-2407-14-423.

7.

Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.

Koyanagi K, O'Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, Lewis K, Thompson JA, Anderson CM, Lutzky J, Amatruda TT, Hersh E, Richards J, Weber JS, Hoon DS.

Clin Cancer Res. 2010 Apr 15;16(8):2402-8. doi: 10.1158/1078-0432.CCR-10-0037. Epub 2010 Apr 6.

8.

Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma.

Khoja L, Shenjere P, Hodgson C, Hodgetts J, Clack G, Hughes A, Lorigan P, Dive C.

Melanoma Res. 2014 Feb;24(1):40-6. doi: 10.1097/CMR.0000000000000025.

PMID:
24201293
9.

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

Bitting RL, Healy P, Halabi S, George DJ, Goodin M, Armstrong AJ.

Urol Oncol. 2015 Mar;33(3):110.e1-9. doi: 10.1016/j.urolonc.2014.09.002. Epub 2015 Jan 13.

PMID:
25595577
10.

Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance.

Grisanti S, Almici C, Consoli F, Buglione M, Verardi R, Bolzoni-Villaret A, Bianchetti A, Ciccarese C, Mangoni M, Ferrari L, Biti G, Marini M, Ferrari VD, Nicolai P, Magrini SM, Berruti A.

PLoS One. 2014 Aug 8;9(8):e103918. doi: 10.1371/journal.pone.0103918. eCollection 2014.

11.

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ.

J Clin Oncol. 2008 Jul 1;26(19):3213-21. doi: 10.1200/JCO.2007.15.8923. Erratum in: J Clin Oncol. 2009 Apr 10;27(11):1923.

PMID:
18591556
12.

Future of circulating tumor cells in the melanoma clinical and research laboratory settings.

De Souza LM, Robertson BM, Robertson GP.

Cancer Lett. 2017 Apr 28;392:60-70. doi: 10.1016/j.canlet.2017.01.023. Epub 2017 Feb 2. Review.

PMID:
28163189
13.
14.

Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance.

Khoja L, Lorigan P, Dive C, Keilholz U, Fusi A.

Ann Oncol. 2015 Jan;26(1):33-9. doi: 10.1093/annonc/mdu207. Epub 2014 Jun 6. Review.

PMID:
24907634
15.

Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms.

Khan MS, Kirkwood AA, Tsigani T, Lowe H, Goldstein R, Hartley JA, Caplin ME, Meyer T.

Clin Cancer Res. 2016 Jan 1;22(1):79-85. doi: 10.1158/1078-0432.CCR-15-1008. Epub 2015 Jul 21.

16.

Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.

Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C.

J Clin Oncol. 2012 Feb 10;30(5):525-32. doi: 10.1200/JCO.2010.33.3716. Epub 2012 Jan 17.

PMID:
22253462
17.

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.

Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M.

Breast Cancer Res. 2011 Jun 15;13(3):R67. doi: 10.1186/bcr2907.

18.

Circulating tumor cells in newly diagnosed inflammatory breast cancer.

Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM.

Breast Cancer Res. 2015 Jan 9;17:2. doi: 10.1186/s13058-014-0507-6.

19.

mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.

Mostert B, Sieuwerts AM, Bolt-de Vries J, Kraan J, Lalmahomed Z, van Galen A, van der Spoel P, de Weerd V, Ramírez-Moreno R, Smid M, Verhoef C, IJzermans JN, Gratama JW, Sleijfer S, Foekens JA, Martens JW.

Mol Oncol. 2015 Apr;9(4):920-32. doi: 10.1016/j.molonc.2015.01.001. Epub 2015 Jan 21.

20.

Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.

Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, Ranson M, Blackhall FH, Dive C.

J Thorac Oncol. 2012 Feb;7(2):306-15. doi: 10.1097/JTO.0b013e31823c5c16.

Supplemental Content

Support Center